within Pharmacolibrary.Drugs.ATC.C;

model C02LB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.25,
    Cl             = 0.0021666666666666666,
    adminDuration  = 600,
    adminMass      = 250 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0013,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C02LB01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Methyldopa (levorotatory) is an antihypertensive agent in the centrally acting antiadrenergic class, often used in combination with diuretics for the management of moderate to severe hypertension. It acts as a centrally acting alpha-2 adrenergic agonist, reducing peripheral vascular resistance. This combination was commonly used in the past, particularly in pregnancy-induced hypertension, but methyldopa is less frequently a first-line agent today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for methyldopa (levorotatory) co-administered with diuretics in adult patients, as direct published PK data for this specific combination is not available.</p><h4>References</h4><ol><li><p>MacCarthy, EP, &amp; Bloomfield, SS (1983). Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. <i>Pharmacotherapy</i> 3(4) 193–219. DOI:<a href=&quot;https://doi.org/10.1002/j.1875-9114.1983.tb03252.x&quot;>10.1002/j.1875-9114.1983.tb03252.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6310529/&quot;>https://pubmed.ncbi.nlm.nih.gov/6310529</a></p></li><li><p>Laurent, S, &amp; Safar, M (1992). Rilmenidine: a novel approach to first-line treatment of hypertension. <i>American journal of hypertension</i> 5(4 Pt 2) 99S–105S. DOI:<a href=&quot;https://doi.org/10.1093/ajh/5.4.99s&quot;>10.1093/ajh/5.4.99s</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1350733/&quot;>https://pubmed.ncbi.nlm.nih.gov/1350733</a></p></li><li><p>Brogden, RN, &amp; Sorkin, EM (1990). Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease. <i>Drugs</i> 40(6) 903–949. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199040060-00010&quot;>10.2165/00003495-199040060-00010</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2079001/&quot;>https://pubmed.ncbi.nlm.nih.gov/2079001</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C02LB01;
